Dino Mustafić

September 29, 2019 Off

Eli Lilly with promising oncology presentations at ESMO

Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer

September 27, 2019 Off

Merck, Pfizer present avelumab’s activity in tumors treatment

By Dino Mustafić

Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.

September 27, 2019 Off

Synairgen uplifted by beginning results of phase 2 trial of antiviral therapy for COPD patients

By Dino Mustafić

Synairgen is confident to get a positive outcome in Part 2 study of Phase 2 trial of its antiviral therapy for Chronic Obstructive Pulmonary Disorder (COPD) patients, in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection, after the first part showed positive results.

September 26, 2019 Off

Sygnature Discovery develops AR molecular visualisation prototype

By Dino Mustafić

Sygnature Discovery has developed an AR molecular visualisation prototype, meaning that scientists could soon be rotating virtual molecules in the world around them.

September 25, 2019 Off

FDA grants approval for Bavarian Nordic’s monkeypox vaccine

By Dino Mustafić

The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.

September 25, 2019 Off

Sequana Medical enrolls first patient testing alfapump for liver cirrhosis-caused ascites

By Dino Mustafić

Belgian Sequana Medical has enrolled the first patient in the North American pivotal study of the alfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis.

September 23, 2019 Off

GW paves way to launch Epidylex in Europe

By Dino Mustafić

GW Pharmaceuticals paved a way to launch Epidyolex in Europe, for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.

September 23, 2019 Off

Faron Pharma operating loss for 6 months down from last years same period

By Dino Mustafić

Faron Pharma posted operating loss of €6.3 million for the six months ended 30 June 2019, cutting it from the same period last year, of €14.0 million.

September 23, 2019 Off

Roche with Tecentriq results in Barcelona

By Dino Mustafić

Roche will present a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

September 23, 2019 Off

Amryt scheme shareholders to receive New Amryt Shares

By Dino Mustafić

Amryt said that Scheme has been sanctioned by the High Court of Justice in England and Wales and the Scheme Court Order is expected to be filed with the Registrar of Companies on 24 September 2019, at which point the Scheme will become effective.